/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Allogene Therapeutics, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.48 0.1343(13.43%) ALLO at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 1.33
Highest Today 1.515
Today’s Open 1.35
Prev. Close 1.34
52 Week High 3.78
52 Week Low 0.86
Day’s Range: Low 1.33 High 1.515
52-Week Range: Low 0.86 High 3.78
1 day return -
1 Week return +4.12
1 month return +38.35
3 month return +35.87
6 month return +18.35
1 year return -32.66
3 year return -83.79
5 year return -95.48
10 year return -

Institutional Holdings

Pfizer Inc 9.93

TPG GP A, LLC 8.44

BlackRock Inc 8.07

American Funds SMALLCAP World A 5.03

Capital World Investors 5.03

Darwin Global Management, Ltd. 4.72

Citadel Advisors Llc 4.62

Vanguard Group Inc 3.72

PRIMECAP Management Company 2.58

Goldman Sachs Group Inc 2.48

Woodline Partners LP 1.97

Vanguard Total Stock Mkt Idx Inv 1.89

T. Rowe Price Associates, Inc. 1.82

Geode Capital Management, LLC 1.71

iShares Russell 2000 ETF 1.61

Vanguard Capital Opportunity Inv 1.61

Wildcat Capital Management, LLC 1.32

Foresite Capital Management VI LLC 1.30

Dimensional Fund Advisors, Inc. 1.23

State Street Corp 1.23

T. Rowe Price Health Sciences 1.23

Patient Square Capital 1.19

BGF World Healthscience A2 1.11

UBS Group AG 0.92

PRIMECAP Odyssey Aggressive Growth 0.91

Vida Ventures Advisors, LLC 0.81

Two Sigma Advisers, LLC 0.80

Vanguard Institutional Extnd Mkt Idx Tr 0.76

abrdn Life Sciences Investors 0.71

Fidelity Small Cap Index 0.69

BlackRock Health Sciences Opps Inv A 0.64

iShares Russell 2000 Value ETF 0.59

Fidelity Select Biotechnology 0.42

iShares Biotechnology ETF 0.40

Fidelity Extended Market Index 0.38

JPM Thematics Genetic Thrps C2 dist USD 0.38

Schwab US Small-Cap ETF™ 0.35

Vanguard Russell 2000 ETF 0.33

Vanguard Health Care ETF 0.21

State St Russell Sm Cap® Indx SL Cl I 0.20

Market Status

Strong Buy: 8

Buy: 4

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 301.14 M

PB Ratio 0.9799

PE Ratio 0.0

Enterprise Value 133.94 M

Total Assets 548.71 M

Volume 3429231

Company Financials

Annual Revenue FY23:186000 0.2M, FY22:243000 0.2M, FY21:38489000 38.5M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:243000 0.2M, FY21:38489000 38.5M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-332855000 -332.9M, FY22:-329815000 -329.8M, FY21:-244837000 -244.8M, FY20:-233471000 -233.5M, FY19:-184594000 -184.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-31164000 -31.2M, Q2/2025:-3106000 -3.1M, Q1/2025:-3099000 -3.1M, Q3/2024:null 0.0M, Q2/2024:-3644000 -3.6M

Quarterly Net worth Q3/2025:-41400000 -41.4M, Q2/2025:-50943000 -50.9M, Q1/2025:-59733000 -59.7M, Q3/2024:-66293000 -66.3M, Q2/2024:-66358000 -66.4M

Fund house & investment objective

Company Information Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 226

Industry Biotechnology

CEO Dr. David D. Chang M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow